Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM versus TENATHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM versus TENATHAN.
NAPROXEN SODIUM vs TENATHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
TENATHAN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin levels in the synaptic cleft.
220-550 mg orally twice daily; maximum 1375 mg/day.
1 tablet (40 mg) orally once daily, increased to 80 mg once daily if needed after 4 weeks.
None Documented
None Documented
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Terminal elimination half-life is 4-6 hours; in severe renal impairment (CrCl <30 mL/min) may extend to 8-12 hours, requiring dose adjustment.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category D/X
Category C
NSAID
NSAID